Cilostazol for primary prevention of stroke in peripheral artery disease: A Population-based longitudinal study in Taiwan

Thrombosis Research

Volumn 132, Issue 2, 2013, Pages 190-195

  Lee, Wen Hsien ^a,b   Chu, Chun Yuan ^a   Hsu, Po Chao ^a   Su, Ho Ming ^a,b,c   Lin, Tsung Hsien ^a,c   Voon, Wen Chol ^a,c   Lai, Wen Ter ^a,c   Sheu, Sheng Hsiung ^a,c  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b KAOHSIUNG MUNICIPAL HSIAO KANG HOSPITAL   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

aspirin; cilostazol; hemorrhage; peripheral artery disease; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; CILOSTAZOL; CLOPIDOGREL;

ADULT; ARTICLE; BLEEDING; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; POPULATION RESEARCH; PRIORITY JOURNAL; TAIWAN;

ASPIRIN; CILOSTAZOL; HEMORRHAGE; PERIPHERAL ARTERY DISEASE; STROKE;

AGED; ASPIRIN; COHORT STUDIES; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; PERIPHERAL ARTERIAL DISEASE; RETROSPECTIVE STUDIES; RISK FACTORS; STROKE; TAIWAN; TETRAZOLES; TICLOPIDINE; VASODILATOR AGENTS;

EID: 84883812707     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2013.01.036     Document Type: Article

References (37)

1. A.T. Hirsch, Z.J. Haskal, N.R. Hertzer, C.W. Bakal, M.A. Creager, and J.L. Halperin ACC/AHA 2005 practice guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): A collaborative report from the american association for vascular surgery/society for vascular surgery, society for cardiovascular angiography and interventions, society for vascular medicine and biology, society of interventional radiology, and the acc/aha task force on practice guidelines (writing committee to develop guidelines for the management of patients with peripheral arterial disease): Endorsed by the american association of cardiovascular and pulmonary rehabilitation; national heart, lung, and blood institute; society for vascular nursing; transatlantic inter-society consensus; and vascular disease foundation Circulation 113 2006 e463 e654
2. R. Cui, H. Iso, K. Yamagishi, T. Tanigawa, H. Imano, and T. Ohira Ankle-arm blood pressure index and cardiovascular risk factors in elderly japanese men Hypertens Res 26 2003 377 382
3. S.S. Kweon, M.H. Shin, K.S. Park, H.S. Nam, S.K. Jeong, and S.Y. Ryu Distribution of the ankle-brachial index and associated cardiovascular risk factors in a population of middle-aged and elderly koreans J Korean Med Sci 20 2005 373 378
4. X. Yang, K. Sun, W. Zhang, H. Wu, H. Zhang, and R. Hui Prevalence of and risk factors for peripheral arterial disease in the patients with hypertension among han chinese J Vasc Surg 46 2007 296 302
5. A. Banerjee, F.G. Fowkes, and P.M. Rothwell Associations between peripheral artery disease and ischemic stroke: Implications for primary and secondary prevention Stroke 41 2010 2102 2107
6. M.H. Criqui, J.O. Denenberg, R.D. Langer, and A. Fronek The epidemiology of peripheral arterial disease: Importance of identifying the population at risk Vasc Med 2 1997 221 226
7. S.W. Cheng, L.L. Wu, H. Lau, A.C. Ting, and J. Wong Prevalence of significant carotid stenosis in chinese patients with peripheral and coronary artery disease Aust N Z J Surg 69 1999 44 47
8. Antithrombotic Trialists' Collaboration Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients BMJ 324 2002 71 86
9. Y. Liu, Y. Shakur, M. Yoshitake, and Ji J. Kambayashi Cilostazol (pletal): A dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake Cardiovasc Drug Rev 19 2001 369 386
10. F.T.H. Gotoh, S. Hirai, A. Terashi, Y. Fukuuchi, E. Otomo, and Y. Shinohara Cilostazol stroke prevention study: A placebo-controlled double-blind trial for secondary prevention of cerebral infarction J Stroke Cerebrovasc Dis 9 2000 147 157
11. Y. Shinohara, Y. Katayama, S. Uchiyama, T. Yamaguchi, S. Handa, and K. Matsuoka Cilostazol for prevention of secondary stroke (CSPS 2): An aspirin-controlled, double-blind, randomised non-inferiority trial Lancet Neurol 9 2010 959 968
12. T. Shinoda-Tagawa, Y. Yamasaki, S. Yoshida, Y. Kajimoto, T. Tsujino, and N. Hakui A phosphodiesterase inhibitor, cilostazol, prevents the onset of silent brain infarction in japanese subjects with type II diabetes Diabetologia 45 2002 188 194
13. S.Y. Rhee, Y.S. Kim, S. Chon, S. Oh, J.T. Woo, and S.W. Kim Long-term effects of cilostazol on the prevention of macrovascular disease in patients with type 2 diabetes mellitus Diabetes Res Clin Pract 91 2011 e11 e14
14. N. Katakami, Y.S. Kim, R. Kawamori, and Y. Yamasaki The phosphodiesterase inhibitor cilostazol induces regression of carotid atherosclerosis in subjects with type 2 diabetes mellitus: Principal results of the diabetic atherosclerosis prevention by cilostazol (DAPC) study: A randomized trial Circulation 121 2010 2584 2591
15. L.J. Lin, M.H. Cheng, C.H. Lee, D.C. Wung, C.L. Cheng, and Y.H. Kao Yang Compliance with antithrombotic prescribing guidelines for patients with atrial fibrillation-a nationwide descriptive study in taiwan Clin Ther 30 2008 1726 1736
16. D.L. Bhatt, K.A. Fox, W. Hacke, P.B. Berger, H.R. Black, and W.E. Boden Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events N Engl J Med 354 2006 1706 1717
17. M.J. Kim, K.G. Park, K.M. Lee, H.S. Kim, S.Y. Kim, and C.S. Kim Cilostazol inhibits vascular smooth muscle cell growth by downregulation of the transcription factor E2F Hypertension 45 2005 552 556
18. N. Ishizaka, J. Taguchi, Y. Kimura, Y. Ikari, T. Aizawa, and M. Togo Effects of a single local administration of cilostazol on neointimal formation in balloon-injured rat carotid artery Atherosclerosis 142 1999 41 46
19. H. Omi, N. Okayama, M. Shimizu, T. Fukutomi, A. Nakamura, and K. Imaeda Cilostazol inhibits high glucose-mediated endothelial-neutrophil adhesion by decreasing adhesion molecule expression via NO production Microvasc Res 68 2004 119 125
20. F. Honda, H. Imai, M. Ishikawa, C. Kubota, T. Shimizu, and M. Fukunaga Cilostazol attenuates gray and white matter damage in a rodent model of focal cerebral ischemia Stroke 37 2006 223 228
21. I. Yuzawa, M. Yamada, and K. Fujii An oral administration of cilostazol before focal ischemia reduces the infarct volume with delayed cerebral blood flow increase in rats J Stroke Cerebrovasc Dis 17 2008 281 286
22. J.M. Choi, H.K. Shin, K.Y. Kim, J.H. Lee, and K.W. Hong Neuroprotective effect of cilostazol against focal cerebral ischemia via antiapoptotic action in rats J Pharmacol Exp Ther 300 2002 787 793
23. J.H. Lee, Y.K. Lee, M. Ishikawa, K. Koga, M. Fukunaga, and G. Miyakoda Cilostazol reduces brain lesion induced by focal cerebral ischemia in rats-an MRI study Brain Res 994 2003 91 98
24. K. Johkura, T.N. Yoshida, Y. Kudo, Y. Nakae, T. Momoo, and Y. Kuroiwa Cilostazol versus aspirin therapy in patients with chronic dizziness after ischemic stroke Clin Neurol Neurosurg 114 2012 876 880
25. J.R. Crouse III, J.S. Raichlen, W.A. Riley, G.W. Evans, M.K. Palmer, and D.H. O'Leary Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: The METERO trial JAMA 297 2007 1344 1353
26. M.A. Espeland, D.H. O'Leary, J.G. Terry, T. Morgan, G. Evans, and H. Mudra Carotid intimal-media thickness as a surrogate for cardiovascular disease events in trials of HMG-CoA reductase inhibitors Curr Control Trials Cardiovasc Med 6 2005 3
27. J.L. Fleg, M. Mete, B.V. Howard, J.G. Umans, M.J. Roman, and R.E. Ratner Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: The SANDS (stop atherosclerosis in native diabetics study) trial J Am Coll Cardiol 52 2008 2198 2205
28. H.C. Diener, J. Bogousslavsky, L.M. Brass, C. Cimminiello, L. Csiba, and M. Kaste Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): Randomised, double-blind, placebo-controlled trial Lancet 364 2004 331 337
29. CAPRIE Steering Committee A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE steering committee Lancet 348 1996 1329 1339
30. Bureau of National Health Insurance Drug indications and payments. Chapter 2: Cardiovascular-renal drugs Available from: http://www.nhi.gov.tw/ webdata/webdata.aspx?menu=20&menu-id=710&WD-ID=812&webdata-id=2919
31. K.H. Mak, D.L. Bhatt, M. Shao, G.J. Hankey, J.D. Easton, and K.A. Fox Ethnic variation in adverse cardiovascular outcomes and bleeding complications in the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance (CHARISMA) study Am Heart J 157 2009 658 665
32. A.R. Assaf, K.L. Lapane, J.L. McKenney, and R.A. Carleton Possible influence of the prospective payment system on the assignment of discharge diagnoses for coronary heart disease N Engl J Med 329 1993 931 935
33. T. Nakano, H. Ohkuma, and S. Suzuki Measurement of ankle brachial index for assessment of atherosclerosis in patients with stroke Cerebrovasc Dis 17 2004 212 217
34. C. Li, H. Wang, S. Chen, Y. Chen, Y. Chiang, and H. Hsu High risk for future events in acute stroke patients with an ankle-brachial index less than 0.9 Acta Cardiol Sin 28 2012 17 24
35. S.H. Meves, C. Diehm, K. Berger, D. Pittrow, H.J. Trampisch, and I. Burghaus Peripheral arterial disease as an independent predictor for excess stroke morbidity and mortality in primary-care patients: 5-year results of the getABI study Cerebrovasc Dis 29 2010 546 554
36. M.A. Allison, G.A. Laughlin, and E. Barrett-Connor Association between the ankle-brachial index and carotid intimal medial thickness in the Rancho Bernardo Study Am J Cardiol 98 2006 1105 1109
37. M.M. McDermott, K. Liu, M.H. Criqui, K. Ruth, D. Goff, and M.F. Saad Ankle-brachial index and subclinical cardiac and carotid disease: The multi-ethnic study of atherosclerosis Am J Epidemiol 162 2005 33 41